Making clinical trials analyses go faster. And reveal more.
We take a whole new approach to the analysis of clinical trial image data. Unique to the industry we hold 11 patents covering image analysis systems, software and biomarkers. We believe our methods enable us to provide sponsors with information that is more reliable than that acquired through current methodologies. Our semi-automated systems measure and monitor disease progression and changes in biological processes over time. This process provides highly reproducible results, enabling us to measure and monitor minute changes in biological structures and functions, both rapidly and with a high degree of confidence.
The promise of reproducibility.
Reproducible medical image analysis is driven by algorithms that enable quantitative, volumetric measurement of structures and metabolic functions. Guided by this information present in the images, as well as embedded anatomical knowledge, the algorithms enable segmentation of different anatomical structures such as lesions, plaques, bone, muscle, fat and fluid.
Current methodologies for image analysis can be time-consuming, inaccurate and highly variable. Even when the exact same data is being repetitively measured, results can vary from measurement to measurement, technologist to technologist and from radiologist to radiologist. Our patented, semi-automated methods minimize much of this variability, providing highly reproducible measurements throughout the trial lifecycle. Published studies have shown that our semi-automated processes consistently yield a lower coefficient of variation than from manual techniques.*
Our methods provide several significant benefits:
- Level of reproducibility that was previously unattainable
- Less dependence on a single reader
- Greater precision
- Higher throughput
- Smaller sample sizes
- Shorter analysis times
- Shorter trial times
- Significantly reduced costs
*We have been able to achieve a documented low scan-rescan coefficient of variability which is reflected in a high level of measurement precision allowing us to detect differences among small cohorts at varying doses. This makes it possible to establish dose-response relationships early in a development program with the potential for finding a biologically optimal dose at a different level than Maximum Tolerated Dose.